Going beyond the mean: economic benefits of myocardial infarction secondary prevention.

ABSTRACT:

Background

Using the example of secondary prophylaxis of myocardial infarction (MI), our aim was to establish a framework for assessing cost consequences of compliance with clinical guidelines; thereby taking cost trajectories and cost distributions into account.

Methods

Swiss mandatory health insurance claims from 1840 persons with hospitalization for MI in 2014 were analysed. Included persons were predominantly male (74%), had a median age of 73 years, and 71% were pre-exposed to drugs for secondary prophylaxis, prior to index hospitalization. Guideline compliance was defined as being prescribed recommended 4-class drug prophylaxis including drugs from the following four classes: beta-blockers, statins, aspirin or P2Y₁₂ inhibitors, and angiotension-converting en

SUBMITTER: von Wyl V 

PROVIDER: S-EPMC7718707 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature